Clinical Trial

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

Name: A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy — clinical trial record (NCT07305974)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study looks at how well and safely RG002C0106 works for patients with certain kidney disease: primary IgA nephropathy. It's a phase IIa trial done at several locations where both patients and doctors unknow what treatment is being given.

Trial Details

NCT Number	NCT07305974
Lead Sponsor	Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Conditions	IgA Nephropathy (IgAN)
Enrollment	30 participants
Start Date	2025-09-08
Primary Completion	2029-03-31 (estimated)
Study Completion	2029-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-26